Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

US8598202B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Richard Apodaca · San Diego, US
• J. Guy Breitenbucher · Escondido, US
• Alison L. Chambers · San Diego, US
• Xiaohu Deng · San Diego, US
• Natalie A. Hawryluk · San Diego, US
• John M. Keith · San Diego, US
• Neelakandha S. Mani · San Diego, US
• Jeffrey E. Merit · Stanford, US
• Joan Pierce · Raleigh, US
• Mark Seierstad · Escondido, US
• Wei Xiao · San Diego, US

Key dates

• Filing date: Feb 18, 2009
• Grant date: Dec 3, 2013
• Expiry date: Jul 16, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.